SuperDopa

SuperDopa (also referred to as SuperDopamine) is a disease-modifying small molecule prodrug developed by ATED Therapeutics for the treatment of Parkinson's disease. It consists of levodopa (L-dopa) conjugated with the antioxidant N-acetylcysteine (NAC) via a peptide bond, a design intended to facilitate the delivery of both components across the blood-brain barrier. Upon administration, SuperDopa releases levodopa to replenish dopamine levels in the substantia nigra pars compacta and NAC to provide antioxidant and anti-inflammatory effects. Preclinical studies have demonstrated that SuperDopa relieves motor disabilities, reduces alpha-synuclein expression and oligomerization, and attenuates oxidative stress-induced inflammatory pathways, specifically by reversing the phosphorylation of c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38 MAPK). The drug is currently in preclinical development, with the company preparing for Phase I clinical trials.

Other names

SuperDopamineL-dopa-NAC conjugate